Sun X F, Carstensen J M, Stål O, Zhang H, Nordenskjöld B
Department of Oncology, University Hospital of Linköping, Sweden.
APMIS. 1995 Apr;103(4):309-15. doi: 10.1111/j.1699-0463.1995.tb01112.x.
Overexpression of the c-erbB-2 oncogene has been demonstrated in a variety of tumours, including colorectal tumours. In breast carcinoma, c-erbB-2 overexpression is associated with DNA ploidy, some other prognostic indicators, and unfavourable survival prospects. However, there is little such information available regarding colorectal tumours. In this study, c-erbB-2 was analysed retrospectively by immunohistochemistry in 293 primary colorectal adenocarcinomas to assess its relation to DNA ploidy, S-phase fraction, other prognostic factors, and patient survival. Using the monoclonal antibody NCL-CB11, we found that 23% of the tumours were strongly c-erbB-2 positive, while 36% showed weak expression. The highest frequency of c-erbB-2 expression was 81% in DNA tetraploid tumours, compared to 63% in aneuploid and, 53% in diploid tumours (test for heterogeneity, p = 0.031). Overexpression of c-erbB-2 indicated a favourable prognosis in patients with DNA aneuploid tumours (p = 0.0088), but not in those with diploid or tetraploid tumours. The prognostic value of c-erbB-2 in DNA aneuploid tumours remained even after adjustment for Dukes' stage (p = 0.027). The results suggest that a combination of c-erbB-2 expression and DNA ploidy may improve the identification of patients' risk of cancer death.
c-erbB-2癌基因的过表达已在包括结直肠肿瘤在内的多种肿瘤中得到证实。在乳腺癌中，c-erbB-2过表达与DNA倍体、其他一些预后指标以及不良的生存前景相关。然而，关于结直肠肿瘤的此类信息却很少。在本研究中，通过免疫组织化学对293例原发性结直肠腺癌进行回顾性分析c-erbB-2，以评估其与DNA倍体、S期分数、其他预后因素以及患者生存的关系。使用单克隆抗体NCL-CB11，我们发现23%的肿瘤c-erbB-2呈强阳性，而36%呈弱阳性表达。c-erbB-2表达的最高频率在DNA四倍体肿瘤中为81%，相比之下非整倍体肿瘤中为63%，二倍体肿瘤中为53%（异质性检验，p = 0.031）。c-erbB-2过表达表明DNA非整倍体肿瘤患者预后良好（p = 0.0088），但二倍体或四倍体肿瘤患者并非如此。即使在调整Dukes分期后，c-erbB-2在DNA非整倍体肿瘤中的预后价值依然存在（p = 0.027）。结果表明，c-erbB-2表达与DNA倍体相结合可能会改善对癌症死亡风险患者的识别。
